Takeda Pharmaceuticals has decided to wrap up the remaining Actos linked bladder cancer lawsuits. Takeda settled two more claims this week, after a two-month trial in Nevada state court. Recently, Takeda ear-marked $2.4 billion for settlements to settle thousands of personal injury and defective product liability lawsuits brought by diabetic…
There are several thousand lawsuits filed by folks both in state and federal courts by patients who took the prescription drug pioglitazone, sold as brand name Actos and later developed bladder cancer. Doctors prescribe Actos to treat patients with Type 2 Diabetes. Takeda Actos Bladder Cancer Verdict On April 7, 2014,…
After a record breaking pharmaceutical $9 billion jury verdict involving Actos bladder cancer lawsuit, Takeda Pharmaceuticals and Eli Lilly, Actos manufacturers, have filed for a new trial. Takeda Pharmaceuticals and Eli Lilly, claim that the massive award shows that the jury acted with “passion and prejudice”. Actos Record $9B Verdict…
The jury in federal court in Louisiana, sent a loud and clear message on Monday, in rendering a bombshell verdict. Takeda Pharmaceutical Co. and Eli Lilly & Co. were ordered to pay a combined $9 billion in punitive damages. The federal court jury found they hid the cancer risks of…
After 33 grueling days of hotly contested trial testimony, the first federal Actos bladder cancer lawsuit trial has ended. The jury is scheduled to hear closing arguments on Monday and then deliberations will begin. Federal Actos Trial: The Details Terrance Allen’s trial began on February 3, as the first chosen…
ShaA late January trial is scheduled to begin for the first federal Actos trial. This trial is set to begin on January 27 in the U.S. District Court for the Western District of Louisiana, and will be the first to go before a jury in the federal multidistrict litigation (MDL),…
All Byetta, Januvia, Janumet and Victoza cancer lawsuits are consolidated and centralized as part of an MDL, or Multidistrict Litigation. These product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.” The product liability cases are…
The U.S. Judicial Panel on Multidistrict Litigation (JPML) has agreed to consolidate all Byetta, Januvia, Janumet and Victoza cancer lawsuits, centralizing the litigation as part of an MDL, or Multidistrict Litigation. The JPML issued a Transfer Order on August 26, and these product liability cases involve pancreatic cancer after the…
According to the FDA, there is no scientific evidence to confirm that a group of type 2 diabetes drugs called GLP-1 inhibitors is linked to pancreatic cancer. The FDA decision comes on the heels of the European Medicines Agency, which stated that they have been unable to confirm an increased…
The National Institutes of Health held a workshop, addressing the risks associated with the newer diabetic drugs. These medications, known as Incretic Mimetics are coming under fire for alleged increased risk of pancreatic cancer. Merck & Co., Novo Nordisk A/S and others, the manufacturers of these drugs may be asked…